Read our latest updates & insights

As reported in April this year, Celltrion presented the 78-week results of its Phase 3 study of CT-P41, biosimilar to Amgen’s Prolia® (denosumab), at the World Congress on Osteoporosis held in London from 11-14 April 2024.  On 6 August 2024, Celltrion announced that the res...

On 6 August 2024, Health New Zealand announced that it will now allow a small group of cancer patients to receive free early access to MSD’s Keytruda® (pembrolizumab) despite deciding earlier this week that it would not do so.

Pharmac is due to provide Keytruda® fund...

On 6 August 2024, Amgen announced its financial results for Q2/2024, reporting total revenues increased 20% to US$8.4 billion compared with Q2/2023.  Twelve of its products delivered at least double-digit sales growth in the quarter, including Prolia® (denosumab), Repatha® ...

On 6 August 2024, MSD announced that it has expanded its existing global development and commercialisation agreement with Daiichi Sankyo to include MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).  Under the deal, the companies will jointly develop and commer...

On 5 August 2024, Lupin announced the successful completion of a global Phase III clinical study of LUBT010, its biosimilar to Genentech’s Lucentis® (ranibizumab).  The study showed that LUBT010 has comparable efficacy, safety and immunogenicity to Lucentis® in patients wit...

On 2 August 2024, Australia’s Therapeutic Goods Administration announced that, according to Novo Nordisk, Wegovy® (semaglutide), specifically indicated for weight loss, will be available in Australia from early August 2024. While Wegovy® has been approved in Australia since...

On 1 August 2024, Xbrane Biopharma announced that it will regain full rights to XcimzaneTM (BIIB801) biosimilar to UCB’s Cimzia® (certolizumab pegol) for rheumatoid arthritis and psoriasis.  Xbrane and Biogen had entered into a commercialisation and licensing agreement in F...

On 1 August 2024, Pharmacy Daily reported that Bristol Myers Squibb’s (BMS) Opdivo® (nivolumab) has had a new indication for resectable non-small cell lung cancer (NSCLC) listed on Australia’s Pharmaceutical Benefits Scheme (PBS).  It now joins MSD’s Keytruda® (pembrolizuma...

On 1 August 2024, the PBS published its Summary of Changes, which included listing Pfizer’s Abrilada®, biosimilar to AbbVie’s Humira® (adalimumab), on the PBS in 20mg/0.4mL and 40mg/0.8mL dosage injections.

This comes three years after Abrilada was first recommended ...